Spot gold slipped 1.1% to $4,422.91 per ounce by 10:50 a.m. EDT (1447 GMT), putting it on track for a mild weekly decline. After ‌the data, ⁠bullion fell ⁠more than 2% to an intraday low of $4,364.99 per ounce.

U.S. gold futures for December delivery dropped ​1.5% to $4,469.80 per ounce.

U.S. job growth accelerated sharply in August while the unemployment rate held steady at 4.1%, pointing to a still stable labor market and keeping an interest rate hike from the Federal Reserve this month on the table.

“Gold stumbles ​badly as a huge headline print, and an overall ⁠strong report, ‌makes a September rate hike much more likely unless we ​get a ​weak CPI report,” independent analyst Tai Wong said.

Live Events

Short-term interest rate ⁠futures prices now imply about a 65% chance of an ​increase in the U.S. policy rate at the Fed’s ​September 15 to 16 meeting, up from about 55% before the Bureau of Labor Statistics report.
The focus now shifts to next week’s U.S. consumer and producer price inflation data, which could provide further clues on the Federal Reserve’s policy path.”This latest jobs report follows Chair Warsh’s hawkish speech at Jackson Hole and ‌appears to have cracked the door even wider for the Fed to follow through with its hiking bias, perhaps as soon as ​this month,” ​said Han Tan, chief ⁠market analyst at Bybit.

“With the price stability mandate at the forefront of policymakers’ minds, next week’s U.S. CPI prints may yet trigger bigger moves for the precious ​metal,” added Han.

Meanwhile, the U.S. dollar jumped after the report, making greenback-denominated gold more expensive for holders of other currencies. [USD/]

Among other metals, spot silver fell 1.7% to $65.79 per ounce, platinum slipped 0.8% to $1,811.83 per ounce, and palladium dropped 1.6% to $1,397.75. All three metals were headed for a weekly decline.

The dollar gave up some ​of its early gains, however, as U.S. markets head into a three-day holiday weekend and as traders waited on next week’s inflation data. Labor Day on Monday is a U.S. public holiday.

August’s job gains followed an unexpected 23,000 job decline in July. The unemployment rate held steady at ‌4.1%.

“I don’t think ⁠this number ⁠changes anything really,” said Noel Dixon, senior macro strategist at State Street, pointing ahead to next week’s inflation reading. “It’s all going to boil down to what ​that core number is going to be next week and I think the markets are going to react accordingly.”

Economic data for August ​is seen as key to whether the Fed will hike at its September 15-16 meeting. Fed Governor Christopher Waller said on Thursday that if upcoming data confirms inflation pressures are cooling off, he is inclined to argue in favor of keeping ​interest rates steady.

Live Events

Producer price inflation data is due on Thursday and consumer price ⁠inflation data is ‌scheduled for Friday next week. Economists expect core CPI to ease to 2.4% on the year, from ​2.5% in July.
Elements ​of Friday’s jobs data also supported slowing inflation, Dixon said.”In today’s number the unemployment rate ⁠stayed steady but if you look at wages year over year, that’s the ​lowest since June 2021. So if Waller and (Fed Chairman Kevin) Warsh and (Fed Bank of New ​York President John) Williams, who I think are very influential, wanted to hang their hat on something, they could hang it on that,” Dixon added.

Wages increased 3.1% in the 12 months through August after rising 3.2% in July.

Fed funds futures traders raised bets on a September hike to 57%, from 50% before the data.

The dollar index, which measures the greenback against a basket of currencies including the yen and the euro, rose 0.21% to 99.17, with the euro down 0.12% at $1.1611.

YEN SURGE

Against the ‌Japanese yen, the dollar strengthened 0.26% to 156.19.

The yen has surged this week, however, as traders boost bets on more or faster Bank of Japan interest rate hikes, and it is testing the 155.21 level, ​which was its ​high after last month’s U.S.-Japan intervention. ⁠If it breaks through that, it will reach its strongest level since May 6.

Japan’s top currency diplomat, Atsushi Mimura, said on Friday he remained on alert to exchange-rate moves, maintaining a warning on Tokyo’s readiness to intervene in the market ​to combat excessive yen declines.

Traders are also speculating on whether Japanese investors, including insurance companies and pension funds, will pull investments out of U.S. Treasuries and into Japanese government bonds as Japanese debt yields rise.

JPMorgan said expectations for Japanese pension fund repatriation and BOJ rate hikes “look somewhat overdone” at the moment, but added that an unwinding of an estimated 16 trillion to 17 trillion yen ($102.36 billion to $108.76 billion) in yen shorts could send the dollar to a 142-to-146 range against the Japanese currency.

In cryptocurrencies, bitcoin fell 2.32% to $79,595.

This article was written by

Follow

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Operator

Good morning, and welcome to the Eurocell plc Half Results Investor Presentation. [Operator Instructions]. Before we begin, I would like to submit the following poll.

I would now like to hand you over to our CEO, Will Truman. Good morning to you.

William Truman
CEO & Executive Director

Good morning, and welcome to Eurocell’s 2026 Half Year Results Presentation. As just introduced, I’m Will Truman, Chief Executive; and I’m with Michael Scott, CFO; also joined with Matt Worster who’s the CFO Designate. This morning, I’ll give you a brief overview of the half year before handing over to Michael, who will take you through the financial results in more detail before handing back to me for the strategy update. Michael will then cover the ERP upgrade, restructuring and ESG, and I will then wrap up with the summary.

As you know, I was appointed in February of this year and my reflection on this first half year’s results is that we’ve made some good progress. Alunet has continued to trade in line with our expectations, and there has been an improvement in the underlying business despite a soft first quarter to the year. The improvement in the sales momentum we saw in Q2 has continued into the second half of the year. As part of this, we have seen gains in each of the strategic initiatives, but importantly, in the underlying business as well.

Alongside this, we have made progress with further restructuring and strong cost disciplines. As a result, group revenues improved 6% in comparison to the first half of the prior year from GBP 193 million to GBP 205 million. Adjusted operating profit

This article was written by

Follow

Analyst’s Disclosure: I/we have a beneficial long position in the shares of IIPR, O, IIPR.PR.A either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

BOSTON — Genetically engineered pig kidneys have been successfully transplanted into five patients at Massachusetts General Hospital, marking a significant milestone in the decades-long effort to use animal organs to address a persistent shortage of human transplant organs, according to results from an ongoing clinical trial.

The five patients underwent xenotransplantation, the process of transplanting organs between species, since March 2024, according to U.S. biotechnology company eGenesis, which developed the genetically modified pig kidneys used in the procedures. In three of the five patients, the transplanted organs continued functioning for more than eight months without triggering rejection or requiring the patient to return to dialysis.

Leonardo Riella, director of kidney transplantation at Massachusetts General Hospital, who led the eGenesis clinical trials, described the scale of the challenge the research aims to address.

“The organ shortage is the greatest crisis we have right now in transplantation,” Riella said.

Mike Curtis, chief executive of eGenesis, characterized the results as a meaningful advance toward the company’s broader goal of expanding access to transplantation.

“It’s amazing to see the progress,” Curtis said. “Our goal is to make transplantation available to patients when they need it, without being constrained by the limited supply of human donor organs.”

The pig kidneys used in the trial were grown in Yucatan miniature pigs, a breed selected in part because their organs are similar in size to human organs. Researchers genetically engineered the pigs to remove three specific pig proteins most likely to trigger immune rejection in human recipients, while adding seven human genes intended to improve compatibility between the transplanted organ and the recipient’s body. Researchers also manipulated the porcine DNA to inactivate viruses that could otherwise pose an infection risk to transplant recipients.

Riella said the animal organs are initially envisioned as a bridge therapy, helping patients avoid dialysis while they wait for a human donor kidney to become available, rather than as a permanent, standalone replacement for human organ transplants at this stage.

“As a bridge to get patients off dialysis while they wait for a human donor kidney,” Riella said, describing the initial intended use of the pig kidneys. He added that the approach could eventually serve “as a destination therapy in its own right” if ongoing trials succeed in establishing long-term safety and durability for the procedure.

One of the five patients, Tim Andrews, whose case was detailed in a study published in The Lancet medical journal, lived with a pig kidney for nearly nine months without requiring dialysis, after receiving the transplant at age 66. The organ eventually began to fail, though doctors found no signs of immune rejection had caused the decline. Andrews subsequently received a kidney from a deceased human donor. Follow-up testing showed that having lived with the pig kidney beforehand did not make it more difficult for the subsequent human donor kidney to function successfully in his body.

Curtis said the U.S. Food and Drug Administration has authorized an expanded clinical trial involving 33 patients with renal failure, set to begin early next year across as many as 10 transplant centers throughout the United States. EGenesis is targeting marketing approval for the pig kidney treatment by the end of 2029. The company is also collaborating with Japanese partner PorMedTec to begin kidney xenotransplantation trials in Japan starting in 2028, according to Curtis.

David Crosby, chief research officer at the renal charity Kidney Research UK, described the results as encouraging while cautioning that significant additional research remains necessary before the approach can be fully evaluated against existing treatment options.

Crosby called the breakthrough “an exciting prospect” but said further research was needed to determine whether the xenotransplantation approach ultimately proves “safer and better” for patients compared with spending years on dialysis while awaiting a conventional human organ transplant.

Xenotransplantation research has moved through repeated cycles of optimism and disappointment since serious scientific investigation into the field began in the 1980s. Researchers and industry officials say recent advances in animal cloning, genetic engineering and immunology have meaningfully improved the field’s prospects compared with earlier decades, when similar research repeatedly failed to produce durable clinical results.

Curtis said public squeamishness and ethical objections to breeding animals specifically for organ transplantation have also diminished over time, as the field has produced increasingly tangible clinical outcomes for patients facing organ failure.

“Hard to sustain … when you look at the outcomes for our patients,” Curtis said, describing his view of moral objections to xenotransplantation given the results seen in the current trial.

Much of the earlier history of xenotransplantation research focused on heart transplants rather than kidneys, but kidney xenografts have since emerged as the area closest to achieving formal clinical approval. Curtis pointed to a key practical advantage kidneys hold over hearts in this context.

“A big advantage of the kidney is that if the transplant fails we can safely return the patient to dialysis,” Curtis said. “If the transplanted heart fails, there’s not much you can do.”

Despite that advantage favoring kidney research, both eGenesis and a separate leading U.S. xenotransplant company, United Therapeutics, are continuing to pursue research involving both organ types. The FDA has separately approved a small trial of xenotransplanted hearts led by United Therapeutics, indicating continued institutional interest in expanding the approach beyond kidneys alone.

The results from the Massachusetts General Hospital trials add to a small but growing body of clinical evidence suggesting genetically engineered animal organs may eventually offer a viable supplement to the existing human donor organ system, which has long struggled to meet demand from patients suffering from kidney failure and other organ-related illnesses. With an expanded 33-patient trial set to begin early next year across multiple U.S. transplant centers, researchers are hoping to build a larger evidentiary base to support the therapy’s eventual path toward regulatory approval later this decade.

For patients like Andrews, whose experience illustrated both the potential and current limitations of the technology, the trial results offer a tangible example of how genetically modified pig organs might eventually help bridge the gap between diagnosis of organ failure and the long wait many patients currently face for a compatible human donor organ, even as researchers caution that substantial additional evidence will be needed before the approach becomes a widely available treatment option.